Sarepta Therapeutics Announces Inducement Grants Under

0
90


CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the chief in precision genetic medication for uncommon ailments, granted fairness awards on September 30, 2022 that had been beforehand authorized by the Compensation Committee of its Board of Directors below Sarepta’s 2014 Employment Commencement Incentive Plan, as a fabric inducement to employment to 43 people employed by Sarepta in September 2022. The fairness awards had been authorized in accordance with Nasdaq Listing Rule 5635(c)(4).

The staff obtained, within the mixture, choices to buy 53,575 shares of Sarepta’s frequent inventory, and within the mixture 27,525 restricted inventory items (“RSUs”). The choices have an train value of $110.54 per share, which is the same as the closing value of Sarepta’s frequent inventory on September 30, 2022 (the “Grant Date”). One-fourth of the shares underlying every worker’s possibility will vest on the one-year anniversary of the Grant Date and thereafter 1/forty eighth of the shares underlying every worker’s possibility will vest month-to-month, such that the shares underlying the choice granted to every worker can be totally vested on the fourth anniversary of the Grant Date, in every case, topic to every such worker’s continued employment with Sarepta on such vesting dates.

One-fourth of the RSUs will vest yearly on every anniversary of the Grant Date, such that the RSUs granted to every worker can be totally vested on the fourth anniversary of the Grant Date, in every case, topic to every such worker’s continued employment with Sarepta on such vesting date.

See also  Heartfulness Meditation reduces vengeful attitude in Youth through increase in positive motivation

About Sarepta Therapeutics
Sarepta is on an pressing mission: engineer precision genetic medication for uncommon ailments that devastate lives and reduce futures quick. We maintain management positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we at the moment have greater than 40 packages in varied levels of growth. Our huge pipeline is pushed by our multi-platform Precision Genetic Medicine Engine in gene remedy, RNA and gene enhancing. For extra info, please go to www.sarepta.com or comply with us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely put up info which may be necessary to traders within the ‘For Investors’ part of our web site at www.sarepta.com. We encourage traders and potential traders to seek the advice of our web site usually for necessary details about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here